Skip to main content
OpenTrials
Completed

NCT Number: NCT00898534

Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus

Immediate feedback of hemoglobin A1c (A1c) results to adults with type 1 and 2 diabetes allows more appropriate care decisions at the clinic visit and may improve glycemic control. The investigators' objective is to determine whether immediate feedback of A1c results to children with type 1 diabetes will improve patient care and glycemic control.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Children's Hospital Boston

Boston, Massachusetts, 02115, United States

About this study

Because glycosylated hemoglobin (A1c) has been shown to reflect average glycemia over several months and has a strong predictive value for diabetes complications, routine quarterly measurements is a standard of care in children and adolescents with Type 1 diabetes mellitus. The A1c value determines whether the patient's glycemic targets have been reached or maintained. The availability of the A1c result at the time the patient is seen (point-of-care testing) has been reported in adults with diabetes to result in increased intensification of therapy and improvement in glycemic control in type 1 and insulin-treated type 2 diabetes and in type 2 diabetes. The A1c may also serve as a check on the accuracy of the patient's glucose meter and the validity of the patient's reported self monitored blood glucose (SMBG) results.

In many clinical settings, A1c is determined in a central laboratory on a blood sample obtained by venipuncture and results usually are available one to two business days after the sample is obtained. If the A1c value is different than predicted from a review of available SMBG data at the visit, the practitioner must contact the family to review the results and, revise any care decisions made during the visit. This system is inefficient and fraught with the potential for less than optimal care relating to delays in the practitioner seeing the result, delays in reaching the subject or parents, and absence of the subject's participation in the phone call updating the care plan. Furthermore, many children dread venipuncture, which is often poorly tolerated and makes clinic visits painful, emotionally traumatic and unpleasant experiences.

Because there are no published data on the utility of point-of-care A1c testing in children and adolescents with diabetes, we designed a prospective randomized controlled trial to determine if subjects who received immediate feedback of A1c results at their clinic visits would have a lower A1c as compared to those who received A1c results after the clinic visit. We intend to determine whether immediate feedback of A1c results will enable the clinicians providing diabetes care to make more adjustments to the subject's management plan at the time of the clinic visit, and whether this will lead to fewer communications with the subject/family between visits. Finally we will assess the relative pain caused by fingerstick blood sampling as compared to venipuncture.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 1 diabetes mellitus diagnosed at least 2 years prior to enrollment in study
  • Less than 18 years of age

Exclusion criteria

  • Cystic fibrosis related diabetes
  • Type 2 diabetes
  • Any other suspected non-type 1 diabetes (e.g., maturity onset diabetes of the young)

Treatment and study plan

Bayer DCA2000+ Hemoglobin A1c analyzer

Device

Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick

Primary outcomes

  1. Hemoglobin A1c

    Time frame: 1 year after enrollment

Secondary outcomes

  1. Hemoglobin A1c

    Time frame: 3, 6, and 9 months after enrollment

  2. Pain rating of hemoglobin A1c test

    Time frame: 3, 6, 9, and 12 months after enrollment

  3. Change in diabetes management (insulin, diet, exercise, glucose self-monitoring)

    Time frame: 3, 6, 9, and 12 months after enrollment

  4. Episodes of severe hypoglycemia

    Time frame: 3, 6, 9, and 12 months after enrollment

  5. Hospital admissions for diabetes related event

    Time frame: 3, 6, 9, and 12 months after enrollment

  6. Number of phone and/or email contacts between practitioner and patient

    Time frame: 3, 6, 9, and 12 months after enrollment

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Registry information

Important dates

Study start
2003
Primary completion
2005
Study completion
2006
First posted
May 12, 2009
Registry last updated
May 12, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.